Relay Therapeutics Inc. Common Stock (RLAY)
Stock · NASDAQ · Health Care
$16.3as of 10/16/2026
Price chart
Active signals
RLAY Signal Track Record
How signals performed across all stocks →What RLAY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -0.3% | 50% | September 8, 2026 |
| Bollinger Band Breakout | 24 | -2.5% | 46% | June 22, 2026 |
| Bollinger Band BreakdownActive now | 22 | -2.1% | 32% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -16.7% | 11% | August 28, 2025 |
| Any 20-session window (baseline) | -0.7% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RLAY
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 202
- Website
- relaytx.com/
Fundamentals
- 1-day range
- $16.13$17.17
- Market cap
- $3.78B
- P/E (trailing)
- —
- P/E (forward)
- -9.97
- EPS (trailing)
- $-1.57
- Dividend yield
- —
- Beta
- 1.71
- Avg. volume
- 2.77M
How Relay Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Relay Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RLAYRelay Therapeutics Inc. Common Stock$16.28▼ 5.90%Market cap $3.78BP/E —$5.95$21.27
- ADPTAdaptive Biotechnologies Corporation Common Stock$24.02▼ 6.10%Market cap $3.77BP/E —$12$30.74
- DNLIDenali Therapeutics Inc. Common Stock$17.61▼ 3.98%Market cap $3.92BP/E —$13.75$27.3
- KODKodiak Sciences Inc Common Stock$85.75▼ 2.69%Market cap $2.84BP/E —$10.94$104
- BEAMBeam Therapeutics Inc. Common Stock$23.47▼ 5.10%Market cap $2.81BP/E —$20.23$38.26
- TARSTarsus Pharmaceuticals Inc. Common Stock$68.07▼ 4.11%Market cap $2.81BP/E —$53.89$91.53
- IOVAIovance Biotherapeutics Inc. Common Stock$13.62▼ 7.47%Market cap $2.77BP/E —$1.76$15.3
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RLAY Relay Therapeutics Inc. Common Stock | $3.78B | — | $16.28 | ▼ 5.90% | $5.95$21.27 |
| ADPT Adaptive Biotechnologies Corporation Common Stock | $3.77B | — | $24.02 | ▼ 6.10% | $12$30.74 |
| DNLI Denali Therapeutics Inc. Common Stock | $3.92B | — | $17.61 | ▼ 3.98% | $13.75$27.3 |
| KOD Kodiak Sciences Inc Common Stock | $2.84B | — | $85.75 | ▼ 2.69% | $10.94$104 |
| BEAM Beam Therapeutics Inc. Common Stock | $2.81B | — | $23.47 | ▼ 5.10% | $20.23$38.26 |
| TARS Tarsus Pharmaceuticals Inc. Common Stock | $2.81B | — | $68.07 | ▼ 4.11% | $53.89$91.53 |
| IOVA Iovance Biotherapeutics Inc. Common Stock | $2.77B | — | $13.62 | ▼ 7.47% | $1.76$15.3 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Raymond James Updates Healthcare Top Picks for OctoberYahoo · 10/1/2026
- Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?Yahoo · 9/24/2026
- Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene EditingSeekingAlpha · 9/24/2026
- X-Chem Announces Phase 3 Milestone in Collaboration with Relay TherapeuticsYahoo · 9/22/2026
- Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →- Patel Sanjiv · October 7, 2026 · Sale48.2K @ $18.1
- Catinazzo Thomas · October 6, 2026 · Sale206 @ $19.26
- Catinazzo Thomas · October 6, 2026 · Sale17.5K @ $18.58
- Catinazzo Thomas · September 8, 2026 · Sale17.7K @ $18.94
- Patel Sanjiv · September 8, 2026 · Sale48.2K @ $18.94
- Bergstrom Donald A · September 8, 2026 · Sale8.5K @ $18.97
- Rahmer Peter · August 26, 2026 · Sale4.5K @ $20.03
- SVF Pauling (Cayman) Ltd · August 25, 2026 · Sale6.00M @ $19.4
- Patel Sanjiv · August 17, 2026 · Sale48.2K @ $20.33
- Catinazzo Thomas · August 14, 2026 · Sale17.7K @ $19.74
- Catinazzo Thomas · July 28, 2026 · Sale1.5K @ $18.61
- Rahmer Peter · July 28, 2026 · Sale748 @ $18.61
- Bergstrom Donald A · July 28, 2026 · Sale2.2K @ $18.61
- Patel Sanjiv · July 7, 2026 · Sale48.2K @ $19.58
- Catinazzo Thomas · July 6, 2026 · Sale17.7K @ $18.69
Institutional Ownership
March 31, 2026
- Total shares held
- 181.35M
- Total value held
- $1.77B
- Institutional holders
- 235
- Unknown27.90M
- Unknown17.00M
- Unknown14.42M
- Unknown12.98M
- Unknown9.75M
- Unknown7.80M
- Unknown7.39M
- Unknown6.23M
- Unknown5.53M
- Unknown4.27M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
RLAY Valuation Debate: Is the Pullback a Value Trap?
Recent analysis questions whether Relay Therapeutics is undervalued after its recent price drop or if the market has already priced in potential gains. One report suggests the stock is fully priced relative to its book value, while another asks if the current level offers a bargain. The stock is currently trading near a key support level, with analysts maintaining a higher average target price.
RLAY Valuation Debate: Is the Pullback a Value Trap?. Recent analysis questions whether Relay Therapeutics is undervalued after its recent price drop or if the market has already priced in potential gains. One report suggests the stock is fully priced relative to its book value, while another asks if the current level offers a bargain. The stock is currently trading near a key support level, with analysts maintaining a higher average target price.